ASP Isotopes Inc. (ASPI)
ASP Isotopes Inc. (ASPI)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -7,121,000 | -63,330,807 | -12,893,602 | -83,618,591 |
| Income from discontinued operations | 249,000 | NaN | NaN | NaN |
| Foreign exchange transaction loss from intercompany | -3,607,000 | 0 | NaN | NaN |
| Non cash in-process research and development | NaN | 2,560,000 | NaN | NaN |
| Depreciation and amortization | 3,057,000 | 936,725 | 975,275 | NaN |
| Allowance for credit losses | NaN | 58,000 | NaN | NaN |
| Loss on disposal of property and equipment | NaN | 0 | 0 | 0 |
| Gain on deconsolidation | 19,336,000 | NaN | NaN | NaN |
| Non cash interest income on note receivable | NaN | 815,856 | 825,346 | 363,798 |
| Non cash interest expense on debt | 2,541,000 | NaN | NaN | NaN |
| Stock-based compensation | 4,412,000 | 5,220,814 | 4,483,808 | 6,319,378 |
| Convertible note payable for non-cash issuance costs | NaN | 0 | 0 | 0 |
| Shares issued for non-cash consultant expense | 0 | -497 | 0 | 673,497 |
| Change in fair value of share liability | 0 | 79,138 | -70,869 | -129,269 |
| Change in fair value of convertible notes payable | -568,000 | -59,176,705 | 172,836 | -64,715,131 |
| Change in fair value of investments | NaN | 17,932,000 | NaN | NaN |
| Change in fair value of equity investments | 1,126,000 | NaN | NaN | NaN |
| Change in right-of-use lease asset | 3,293,000 | 225,547 | 182,501 | 267,952 |
| Depreciation | NaN | NaN | NaN | 678,959 |
| Non-cash lease income | 62,000 | 24,460 | 22,476 | 22,064 |
| Change in deferred taxes | -76,000 | -78,175 | 32,890 | 285 |
| Accounts receivable | 800,000 | 1,585,993 | -1,014,945 | -89,048 |
| Receivable from noncontrolling interest | 0 | 706 | -353 | -28,353 |
| Inventories | 208,000 | -381,759 | -249,293 | 946,052 |
| Prepaid expenses and other current assets | 739,000 | 1,638,905 | 2,508,539 | -1,318,444 |
| Other noncurrent assets | 89,000 | -33,905 | -1,082,891 | -103,204 |
| Accounts payable | -162,000 | 744,367 | -1,069,245 | 1,106,878 |
| Accrued expenses | -1,172,000 | -317,712 | 1,395,595 | -507,883 |
| Operating lease liabilities | -3,251,000 | -246,680 | -172,706 | -275,614 |
| Other current liabilities | -112,000 | -1,137,935 | -2,358 | -767,707 |
| Other noncurrent liabilities | 386,000 | NaN | NaN | NaN |
| Net cash used in operating activities - continuing operations | -16,639,000 | NaN | NaN | NaN |
| Cash used for operating activities - discontinued operations | -1,121,000 | NaN | NaN | NaN |
| Net cash used in operating activities | -17,760,000 | -17,851,042 | -8,857,647 | -11,071,311 |
| Purchases of property and equipment | 6,137,000 | 2,398,224 | 3,148,212 | 4,107,564 |
| Purchases of short-term investments | 35,425,000 | 47,745,000 | NaN | NaN |
| Principal collections from lease receivable | 159,000 | 26,000 | NaN | NaN |
| Cash advance paid for property and equipment | 0 | 0 | NaN | NaN |
| Cash advance in exchanges for note receivable | NaN | 0 | 0 | 30,000,000 |
| Purchase of equity investments | 10,000,000 | 22,995,000 | 5,000,000 | NaN |
| Cash received for acquisition of business, net of cash paid | -4,919,000 | 2,069,797 | -6,643,797 | NaN |
| Cash disposed of upon deconsolidation of subsidiary | -50,699,000 | NaN | NaN | NaN |
| Net cash used in investing activities - continuing operations | -97,183,000 | NaN | NaN | NaN |
| Net cash used in investing activities | -97,183,000 | -75,182,021 | -1,504,415 | -34,107,564 |
| Payment of notes payable | NaN | NaN | NaN | 409,696 |
| Payment of principal portion of bank loans | NaN | NaN | NaN | 392,263 |
| Proceeds from exercise of warrants | NaN | -312 | 0 | 4,915,312 |
| Proceeds from issuance of common stock | NaN | 210,304,000 | 60,000,000 | 50,000,000 |
| Proceeds from exercise of options | NaN | 6,000 | NaN | NaN |
| Proceeds from issuance of convertible notes payable | NaN | 42,171,000 | 0 | 0 |
| Due to related parties | NaN | 1,980,805 | 590,195 | NaN |
| Proceeds from bank loans | NaN | NaN | NaN | 47,045 |
| Contributions from noncontrolling interest | NaN | 20,799,000 | NaN | NaN |
| Payment of common stock issuance costs | NaN | 11,032,420 | 3,693,950 | 3,238,630 |
| Proceeds from noncontrolling interest in vie | NaN | 0 | 0 | 0 |
| Payment of deferred issuance costs | 267,000 | 169,000 | NaN | NaN |
| Proceeds from collection of receivable from noncontrolling interest in vie | 0 | 0 | 0 | 0 |
| Distribution to noncontrolling interest in vie | 257,000 | -1,581 | 324,271 | 79,310 |
| Distribution to noncontrolling interest of renergen | 380,000 | NaN | NaN | NaN |
| Proceeds from issuance of debt | 53,000 | 12,701,534 | 2,804,466 | NaN |
| Payment of principal portion of debt | 1,823,000 | 12,373,447 | 3,384,553 | NaN |
| Payment of principal portion of finance leases | 44,000 | 273,553 | 42,616 | 61,831 |
| Net cash used in financing activities - continuing operations | -2,718,000 | NaN | NaN | NaN |
| Cash provided by financing activities - discontinued operations | 45,886,000 | NaN | NaN | NaN |
| Net cash provided by (used in) financing activities | 43,168,000 | 264,115,188 | 56,704,185 | 50,780,627 |
| Net change in cash, cash equivalents and restricted cash | -71,775,000 | 171,082,125 | 46,342,123 | 5,601,752 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | -2,044,000 | 538,767 | 108,233 | NaN |
| Cash, cash equivalents and restricted cash - beginning of period | 285,563,000 | 113,942,156 | 61,890,048 | NaN |
| Cash, cash equivalents and restricted cash - end of period | 211,744,000 | 285,563,000 | 113,942,156 | NaN |